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genes within the linkage disequilibrium block deﬁ ned by SNP 
with r2>0.5 with either of the SNP tested. 
Interestingly, many of the RA loci identiﬁ ed, like the one 
conﬁ rmed here, show stronger effects in autoantibody- positive 
subgroups, suggesting that autoantibody positive RA may have 
different  underlying pathogenic mechanisms underpinned by 
Confi rmation of association of the 
REL locus with rheumatoid arthritis 
susceptibility in the UK population
Genome-wide association studies (GWAS) have contributed to 
the identiﬁ cation of at least 14 rheumatoid arthritis (RA) suscep-
tibility loci.1 One of the ﬁ rst RA GWAS included 1522 cases and 
1850 controls from the USA/Sweden and identiﬁ ed TRAF1/C5 
as a novel RA locus.2 This GWAS was recently repeated after 
including an additional 1550 cases and 3310 controls from the 
USA and restricting analysis to US subjects.3 In the expanded 
sample, two novel single nucleotide polymorphisms (SNP) map-
ping to the REL locus showed association with RA. REL encodes 
c-Rel, a member of the nuclear factor kappa B family of transcrip-
tion factors and one of the associated SNP (rs13031237) maps 
to an intron of this gene. The association was validated in an 
independent sample of 2604 RA cases and 2882 controls from 
the USA/Canada, with strong evidence for association in the 
combined samples (rs13031237, p=3.1×10−14). We aimed to test 
the association of the same variants with RA in a large UK case–
control sample.
White patients with RA were recruited from six centres across 
the UK, with ethical committee approval (MREC 99/8/84) and 
after providing informed consent.4 5 Genotyping was performed 
using Sequenom, and only samples and SNP exceeding 90% 
success rate were included in the subsequent analysis. Genotype 
frequencies were compared between cases and controls using 
the trend test implemented in PLINK.6 
DNA samples from 3962 RA cases and 3531 controls were 
available for testing, and the clinical characteristics have 
been described previously.4 5 The two SNP, rs13031237 and 
rs13017599, strongly associated with RA in the previous US/
Canadian study were genotyped in the UK samples and both 
SNP showed strong evidence for association, with no deviation 
from Hardy–Weinberg expectations (table 1). In the previous 
study, the subjects investigated were overwhelmingly positive 
for autoantibodies.3 We, therefore, undertook subgroup analy-
sis in autoantibody-positive groups. The strength of association 
was stronger in anticyclic citrullinated peptide antibody posi-
tive, rheumatoid factor-positive and autoantibody-positive sub-
groups compared with the overall group. A meta-analysis of 
data from the previous US/Canadian sample and the current UK 
group was undertaken and increased the strength of evidence 
for association to 1.7×10−17 (ﬁ gure 1).
In this large sample, we provide conﬁ rmation of association 
of the REL locus with RA in a UK population. The associated 
markers map 28.5 kb apart on chromosome 2p, are in almost 
complete linkage disequilibrium (r2=0.97, D′=1) and, in logis-
tic regression models, it was not possible to determine which 
was driving the association. Rs13017599 is a synonymous sub-
stitution (asparagine) within the ribosomal protein S12 pseudo 
gene 3 (RPS12P3), which is not an obvious candidate RA gene. 
Rs13031237 maps to an intron of REL, which is a stronger can-
didate RA gene because, ﬁ rst, it encodes a component of the 
nuclear factor kappa B signalling 
pathway and, second, c-Rel-deﬁ cient 
mice are resistant to the induction 
of collagen-induced arthritis, sug-
gesting a crucial role for c-Rel in the 
development of systemic autoimmu-
nity.7 There are no other conﬁ rmed 
Table 1 Genotype counts and frequencies for SNP mapping to 
chromosome 2p in UK RA cases and controls and association of SNP in 
subgroups stratifi ed by autoantibody status
 rs13031237 rs13017599
Case, n (%)
 2/2  508 (14.9)  507 (14.8)
 1/2 1674 (49.0) 1672 (48.9)
 1/1 1234 (36.1) 1239 (36.2)
Control, n (%)
 2/2  350 (12.7)  352 (12.8)
 1/2 1271 (46.2) 1270 (46.1)
 1/1 1128 (41.1) 1133 (41.1)
Case–control comparison
 p-Trend   5.26×10−5   6.96×10−5
 Allelic OR (95% CI)   1.16 (1.08 to 1.25)   1.16 (1.08 to 1.25)
RF+ (n=2370) vs controls (n=2758)
 p-Trend   2.83E−06   3.91E−06
 Allelic OR (95% CI)   1.21 (1.12 to 1.31)   1.21 (1.11 to 1.31)
RF− (n=784) vs controls (n=2758)
 p-Trend   0.37   0.42
 Allelic OR (95% CI)   1.06 (0.94 to 1.19)   1.05 (0.93 to 1.18)
Anti-CCP+ (n=1184) vs controls (n=2758)
 p-Trend   2.12E−05   2.67E−05
 Allelic OR (95% CI)   1.24 (1.12 to 1.37)   1.23 (1.12 to 1.36)
Anti-CCP− (n=433) vs controls (n=2758)
 p-Trend   0.34   0.41
 Allelic OR (95% CI)   0.93 (0.8 to 1.08)   0.94 (0.81 to 1.09)
Auto-antibody+ (n=2593) vs controls (n=2758)
 p-Trend   7.71×10−7   1.01×10−6
 Allelic OR (95% CI)   1.22 (1.12 to 1.31)   1.21 (1.12 to 1.31)
1, major allele; 2, minor allele; Anti-CCP+, anti-cyclic citrullinated peptide antibody 
positive; Anti-CCP−, anticyclic citrullinated peptide antibody negative; Auto-
antibody +, positive for either rheumatoid factor or anticyclic citrullinated peptide 
antibodies; OR, odds ratio; RA, rheumatoid arthritis; RF+, rheumatoid factor positive; 
RF−, rheumatoid factor negative; SNP, single nucleotide polymorphism.
Figure 1 Meta-analysis of current UK data with previous data. US and 
US/Canadian allele counts from Gregersen et al.3 Combined 
p value=1.53×10−17. OR, odds ratio.
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different genetic loci compared with autoantibody- negative 
disease. However, it should be noted that the number of 
 autoantibody-negative samples included in studies is often quite 
small.
In summary, we provide conﬁ rmatory support for the asso-
ciation of the REL locus with RA. Fine mapping and functional 
studies will be required to identify the causal variant(s) and 
inform our understanding of how these variants inﬂ uence the 
pathogenesis of RA. 
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